title: The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease.
abstract: Dexlansoprazole modified-release (MR) is the R-enantiomer of lansoprazole and is currently the only proton-pump inhibitor (PPI) with a novel dual delayed release (DDR) formulation. Overall, dexlansoprazole MR demonstrates a similar safety and side-effect profile as lansoprazole. Dexlansoprazole MR has been shown to be highly efficacious in healing erosive esophagitis, maintaining healed esophageal mucosa in patients with erosive esophagitis and controlling symptoms of patients with nonerosive reflux disease (NERD). Recent studies have also demonstrated that dexlansoprazole MR is highly effective in improving nocturnal heartburn, gastroesophageal reflux disease (GERD) related sleep disturbances and bothersome regurgitation. Dexlansoprazole MR is well tolerated and can be taken without regard to food.
authors.affiliation: Professor of Medicine, Case Western Reserve University, Director, Division of Gastroenterology and Hepatology, Head, Esophageal and Swallowing Center, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109, USA.
authors.forename: Ronnie
authors.initials: R
authors.lastname: Fass
authors.affiliation: The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center and Case Western Reserve University, Cleveland, OH, USA.
authors.forename: Rosita
authors.initials: R
authors.lastname: Frazier
keywords: dexlansoprazole modified-release; gastroesophageal reflux disease; proton-pump inhibitor